Bone marrow mast cell immunophenotyping in adults with mast cell disease: A prospective study of 33 patients

Animesh D Pardanani, T. Kimlinger, T. Reeder, C. Y. Li, Ayalew Tefferi

Research output: Contribution to journalArticle

49 Citations (Scopus)

Abstract

The aberrant co-expression of CD2 and CD25 antigens is the immunophenotypic hallmark of neoplastic mast cells, and has been consistently identified on bone marrow mast cells from patients with indolent mast cell disease (MCD). We prospectively analyzed the bone marrow mast cell immunophenotype by multiparametric flow cytometry (FC) for 33 MCD cases, to examine the role of CD2 and CD25 expression in establishing diagnosis, detecting histologically occult bone marrow mast cell infiltration, and assessing treatment response. While CD25 was almost uniformly expressed, only 6 of 13 patients with indolent MCD, 1 of 8 with aggressive MCD, 2 of 7 with MCD and an associated hematological disorder, and none of the 2 patients with either mast cell leukemia or smoldering systemic mastocytosis, expressed CD2. One of three patients with cutaneous mastocytosis had an aberrant CD2+/CD25+ mast cell population suggesting histologically occult bone marrow involvement. CD25 expression was lost in one patient who achieved complete histologic remission with therapy, but not in two patients who achieved a partial remission. In conclusion, CD25, but not CD2, is a reliable marker for neoplastic mast cells, and CD25 expression indicates histologically occult bone marrow infiltration and residual disease after therapy.

Original languageEnglish (US)
Pages (from-to)777-783
Number of pages7
JournalLeukemia Research
Volume28
Issue number8
DOIs
StatePublished - Aug 2004

Fingerprint

Mastocytosis
Immunophenotyping
Mast Cells
Bone Marrow Cells
Prospective Studies
CD2 Antigens
Mast-Cell Leukemia
Cutaneous Mastocytosis
Bone Marrow
Interleukin-2 Receptor alpha Subunit
Systemic Mastocytosis
Flow Cytometry
Therapeutics
Population

Keywords

  • Bone marrow
  • Co-expression
  • Mast cell disease

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

Bone marrow mast cell immunophenotyping in adults with mast cell disease : A prospective study of 33 patients. / Pardanani, Animesh D; Kimlinger, T.; Reeder, T.; Li, C. Y.; Tefferi, Ayalew.

In: Leukemia Research, Vol. 28, No. 8, 08.2004, p. 777-783.

Research output: Contribution to journalArticle

@article{196c34fbd7cf44b888f1b666f820c021,
title = "Bone marrow mast cell immunophenotyping in adults with mast cell disease: A prospective study of 33 patients",
abstract = "The aberrant co-expression of CD2 and CD25 antigens is the immunophenotypic hallmark of neoplastic mast cells, and has been consistently identified on bone marrow mast cells from patients with indolent mast cell disease (MCD). We prospectively analyzed the bone marrow mast cell immunophenotype by multiparametric flow cytometry (FC) for 33 MCD cases, to examine the role of CD2 and CD25 expression in establishing diagnosis, detecting histologically occult bone marrow mast cell infiltration, and assessing treatment response. While CD25 was almost uniformly expressed, only 6 of 13 patients with indolent MCD, 1 of 8 with aggressive MCD, 2 of 7 with MCD and an associated hematological disorder, and none of the 2 patients with either mast cell leukemia or smoldering systemic mastocytosis, expressed CD2. One of three patients with cutaneous mastocytosis had an aberrant CD2+/CD25+ mast cell population suggesting histologically occult bone marrow involvement. CD25 expression was lost in one patient who achieved complete histologic remission with therapy, but not in two patients who achieved a partial remission. In conclusion, CD25, but not CD2, is a reliable marker for neoplastic mast cells, and CD25 expression indicates histologically occult bone marrow infiltration and residual disease after therapy.",
keywords = "Bone marrow, Co-expression, Mast cell disease",
author = "Pardanani, {Animesh D} and T. Kimlinger and T. Reeder and Li, {C. Y.} and Ayalew Tefferi",
year = "2004",
month = "8",
doi = "10.1016/j.leukres.2003.10.035",
language = "English (US)",
volume = "28",
pages = "777--783",
journal = "Leukemia Research",
issn = "0145-2126",
publisher = "Elsevier Limited",
number = "8",

}

TY - JOUR

T1 - Bone marrow mast cell immunophenotyping in adults with mast cell disease

T2 - A prospective study of 33 patients

AU - Pardanani, Animesh D

AU - Kimlinger, T.

AU - Reeder, T.

AU - Li, C. Y.

AU - Tefferi, Ayalew

PY - 2004/8

Y1 - 2004/8

N2 - The aberrant co-expression of CD2 and CD25 antigens is the immunophenotypic hallmark of neoplastic mast cells, and has been consistently identified on bone marrow mast cells from patients with indolent mast cell disease (MCD). We prospectively analyzed the bone marrow mast cell immunophenotype by multiparametric flow cytometry (FC) for 33 MCD cases, to examine the role of CD2 and CD25 expression in establishing diagnosis, detecting histologically occult bone marrow mast cell infiltration, and assessing treatment response. While CD25 was almost uniformly expressed, only 6 of 13 patients with indolent MCD, 1 of 8 with aggressive MCD, 2 of 7 with MCD and an associated hematological disorder, and none of the 2 patients with either mast cell leukemia or smoldering systemic mastocytosis, expressed CD2. One of three patients with cutaneous mastocytosis had an aberrant CD2+/CD25+ mast cell population suggesting histologically occult bone marrow involvement. CD25 expression was lost in one patient who achieved complete histologic remission with therapy, but not in two patients who achieved a partial remission. In conclusion, CD25, but not CD2, is a reliable marker for neoplastic mast cells, and CD25 expression indicates histologically occult bone marrow infiltration and residual disease after therapy.

AB - The aberrant co-expression of CD2 and CD25 antigens is the immunophenotypic hallmark of neoplastic mast cells, and has been consistently identified on bone marrow mast cells from patients with indolent mast cell disease (MCD). We prospectively analyzed the bone marrow mast cell immunophenotype by multiparametric flow cytometry (FC) for 33 MCD cases, to examine the role of CD2 and CD25 expression in establishing diagnosis, detecting histologically occult bone marrow mast cell infiltration, and assessing treatment response. While CD25 was almost uniformly expressed, only 6 of 13 patients with indolent MCD, 1 of 8 with aggressive MCD, 2 of 7 with MCD and an associated hematological disorder, and none of the 2 patients with either mast cell leukemia or smoldering systemic mastocytosis, expressed CD2. One of three patients with cutaneous mastocytosis had an aberrant CD2+/CD25+ mast cell population suggesting histologically occult bone marrow involvement. CD25 expression was lost in one patient who achieved complete histologic remission with therapy, but not in two patients who achieved a partial remission. In conclusion, CD25, but not CD2, is a reliable marker for neoplastic mast cells, and CD25 expression indicates histologically occult bone marrow infiltration and residual disease after therapy.

KW - Bone marrow

KW - Co-expression

KW - Mast cell disease

UR - http://www.scopus.com/inward/record.url?scp=2942596256&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2942596256&partnerID=8YFLogxK

U2 - 10.1016/j.leukres.2003.10.035

DO - 10.1016/j.leukres.2003.10.035

M3 - Article

C2 - 15203275

AN - SCOPUS:2942596256

VL - 28

SP - 777

EP - 783

JO - Leukemia Research

JF - Leukemia Research

SN - 0145-2126

IS - 8

ER -